Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-03-26 4:06 pm Purchase | 2021-03-16 | 13G | Prometheus Biosciences, Inc. RXDX | Cormorant Asset Management, LP | 2,098,022 5.410% | 2,098,022 (New Position) | Filing |
| 2021-03-26 4:05 pm Purchase | 2021-03-16 | 13G | Longboard Pharmaceuticals, Inc. LBPH | Cormorant Asset Management, LP | 1,339,631 9.990% | 1,339,631 (New Position) | Filing History |
| 2021-02-16 3:34 pm Sale | 2020-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS | Cormorant Asset Management, LP | 1,714,269 8.450% | -249,999 (-12.73%) | Filing History |
| 2021-02-16 3:33 pm Sale | 2020-12-31 | 13G | Atea Pharmaceuticals, Inc. AVIR | Cormorant Asset Management, LP | 6,411,355 7.760% | -475,000 (-6.90%) | Filing History |
| 2021-02-16 3:32 pm Sale | 2020-12-31 | 13G | Galecto, Inc. GLTO | Cormorant Asset Management, LP | 86,029 8.510% | -5,220 (-5.72%) | Filing History |
| 2021-02-16 3:24 pm Sale | 2020-12-31 | 13G | Olema Pharmaceuticals, Inc. OLMA | Cormorant Asset Management, LP | 3,195,544 7.960% | -75,000 (-2.29%) | Filing History |
| 2021-02-16 3:16 pm Unchanged | 2020-12-31 | 13G | BioAtla, Inc. BCAB | Cormorant Asset Management, LP | 2,292,060 7.120% | 0 (Unchanged) | Filing History |
| 2021-02-16 3:15 pm Sale | 2021-02-16 | 13G | Stoke Therapeutics, Inc. STOK | Cormorant Asset Management, LP | 1,437,807 3.970% | -350,856 (-19.62%) | Filing History |
| 2021-02-16 3:14 pm Sale | 2020-12-31 | 13G | Cabaletta Bio, Inc. CABA | Cormorant Asset Management, LP | 1,904,424 7.920% | -214,709 (-10.13%) | Filing History |
| 2021-02-16 3:13 pm Sale | 2020-12-31 | 13G | PRINCIPIA BIOPHARMA INC PRNB | Cormorant Asset Management, LP | 0 0.000% | -1,990,922 (Position Closed) | Filing History |
| 2021-02-16 3:12 pm Sale | 2020-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | Cormorant Asset Management, LP | 2,392,297 4.960% | -1,004,353 (-29.57%) | Filing History |
| 2021-02-16 3:11 pm Sale | 2020-12-31 | 13G | Constellation Pharmaceuticals, Inc. CNST | Cormorant Asset Management, LP | 0 0.000% | -2,300,000 (Position Closed) | Filing History |
| 2021-02-16 3:10 pm Sale | 2020-12-31 | 13G | Avidity Biosciences, Inc. RNA | Cormorant Asset Management, LP | 2,464,547 6.570% | -49,998 (-1.99%) | Filing History |
| 2021-02-16 3:09 pm Sale | 2020-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT | Cormorant Asset Management, LP | 0 0.000% | -1,144,537 (Position Closed) | Filing History |
| 2021-02-16 3:08 pm Purchase | 2020-12-31 | 13G | Omeros Corporation OMER | Cormorant Asset Management, LP | 5,000,000 8.100% | 1,900,000 (+61.29%) | Filing History |
| 2021-02-16 3:07 pm Sale | 2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Cormorant Asset Management, LP | 0 0.000% | -1,350,000 (Position Closed) | Filing History |
| 2021-02-16 3:06 pm Purchase | 2020-12-31 | 13G | Forma Therapeutics Holdings, Inc. FMTX | Cormorant Asset Management, LP | 4,460,000 9.970% | 1,080,630 (+31.98%) | Filing History |
| 2021-02-16 3:04 pm Purchase | 2021-12-31 | 13G | Otonomy, Inc. OTIC | Cormorant Asset Management, LP | 2,600,000 5.390% | 100,000 (+4.00%) | Filing |
| 2021-02-16 3:03 pm Sale | 2020-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Cormorant Asset Management, LP | 2,490,065 5.790% | -3 (-0.00%) | Filing History |
| 2021-02-16 3:02 pm Sale | 2020-12-31 | 13G | Agenus Inc. AGEN | Cormorant Asset Management, LP | 356,650 3.700% | -229,275 (-39.13%) | Filing History |